Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment.

Cancer Chemother Pharmacol

Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA.

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-025-04797-2DOI Listing

Publication Analysis

Top Keywords

evaluation pharmacokinetics
4
pharmacokinetics enasidenib
4
enasidenib patients
4
patients hepatic
4
hepatic impairment
4
evaluation
1
enasidenib
1
patients
1
hepatic
1
impairment
1

Similar Publications

Intense hepatobiliary uptake of [Tc]Tc-sestamibi in myocardial perfusion scintigraphy (MPS) often degrades image quality by obscuring the inferior myocardial wall, leading to equivocal studies. While nonpharmacological interventions are inconsistent, the choleretic agent ursodeoxycholic acid (UDCA) could potentially accelerate hepatic clearance. The effectiveness of a convenient, single-dose UDCA intervention has not been rigorously evaluated.

View Article and Find Full Text PDF

Purpose: Tarlatamab is a first-in-class, half-life extended bispecific T-cell engager (BiTE®) immunotherapy targeting delta-like ligand 3 (DLL3) currently approved for the treatment of adult patients with small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Here we report tarlatamab exposure-response relationships to inform dose selection in patients with SCLC.

Experimental Design: Pharmacokinetic data were correlated with therapeutic effect [exposure-response (ER) analyses] for efficacy and safety measures using pooled data from DeLLphi-300 and DeLLphi-301 studies.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) are clinically beneficial but associated with high costs that represent a growing challenge for healthcare budgets and may affect affordability, especially in resource-limited settings. Moreover, the healthcare sector is a significant source of greenhouse gas emissions, and medication-related waste-such as that from vial-based therapies-has been identified as a contributing factor. Alternative dosing strategies could reduce the environmental and financial impact of ICI therapy while maintaining clinical safety and efficacy.

View Article and Find Full Text PDF

Clozapine, the only drug approved by the FDA for treatment-resistant schizophrenia, operates within a narrow therapeutic range (0.35-0.60 mg/mL) and requires titration from 12.

View Article and Find Full Text PDF

Therapeutic oligonucleotides (TOs) represent an emerging modality, which offers a promising alternative treatment option, particularly for intracellular targets. The two types of TOs, antisense oligonucleotides (ASO) and small interfering RNAs (siRNAs), distribute highly into tissues, especially into the liver and the kidneys. However, molecular processes at the cellular level such as the uptake into the cell, endosomal escape, binding to the target mRNA, and redistribution back to the systemic circulation are not well characterized because experimental data and assays are lacking.

View Article and Find Full Text PDF